Education only · provider review required
Semaglutide · GLP-1 receptor agonist, FDA-approved
An approved prescription medicine for type 2 diabetes and chronic weight management — explained without hype.
Medically reviewed by Bernard Garcia, MD
What it is
Semaglutide is a GLP-1 receptor agonist peptide, sold as Ozempic (type 2 diabetes, 2017), Rybelsus (oral, 2019) and Wegovy (chronic weight management, 2021). It is one of the most-studied medicines on this site, with multi-year trials in tens of thousands of people.
Because it is approved, it has a label, contraindications, a side-effect profile and a reporting system — all things research peptides lack. That does not make it appropriate for everyone.
How it works
GLP-1 agonists mimic a gut hormone that slows gastric emptying, increases insulin release when glucose is high and acts on appetite centres in the brain. The approved trials measured A1c and body weight over 68 weeks and longer, with gastrointestinal side effects the most common reason for stopping.
Research status
| Research area | Status |
|---|---|
| Type 2 diabetes | FDA-approved (Ozempic, Rybelsus) |
| Chronic weight management | FDA-approved (Wegovy) |
| Cardiovascular risk reduction | FDA-approved label expansion (Wegovy, 2024) |
| Compounded / online copies | Restricted after shortage ended · FDA warnings |
Status reflects published research context only and is not a statement of safety, efficacy, or suitability for any person.
Is it legal?
Semaglutide is FDA-approved under its brand names. Compounded semaglutide was permitted during the FDA-declared shortage; the shortage was resolved and compounding of copies is now restricted, with FDA warnings about unapproved products. A provider will explain what is lawfully available. This is a general note, not legal advice.
Frequently asked questions
Is semaglutide a peptide?
Yes. It is a modified peptide, and also an FDA-approved medicine — that approval is what separates it from research peptides.
What are the main contraindications?
The label includes personal or family history of medullary thyroid carcinoma or MEN2, and warnings around pancreatitis, gallbladder disease and gastrointestinal effects. A provider reviews these against your history.
Can I get compounded semaglutide?
The FDA shortage listing ended and compounding of copies is restricted. Products sold online outside a pharmacy are a safety risk. Ask a provider what is lawfully available.
Next step
Next step: a 3-minute confidential intake, reviewed by a licensed provider. No treatment is promised or implied.
Free · about 10 minutes · reviewed by a licensed physician
General education · Not medical advice · Provider approval required